Carotid Paragangliomas Related to Form Involving Multiple Systems (Syndromes and Diseases): A Systematic Literature Review

Francisco S Lozano-Sánchez MD, PhD,1,2,3 Angel Muñoz MD, PhD,1,4 José A de las Heras MD, PhD,5,6 Rogelio González-Sarmiento, MD, PhD,3,7 and M Begoña García-Cenador MD, PhD1,3*

1Department of Surgery, School of Medicine, University of Salamanca, Spain
2Service of Angiology and Vascular Surgery, University Hospital, Spain
3Salamanca Institute of Biomedical Research (IBSAL), Spain
4Service of Otorhinolaryngology, School of Medicine, University of Salamanca, Spain
5Department of Biomedical and Diagnostic Sciences, School of Medicine, University of Salamanca, Spain
6Service of Radiology, School of Medicine, University of Salamanca, Spain
7Department of Medicine, School of Medicine, University of Salamanca, Spain

*Corresponding author: M Begoña García-Cenador, MD, PhD, Department of Surgery, School of Medicine, University of Salamanca, 37007 Salamanca, Spain; Salamanca Institute of Biomedical Research (IBSAL), 37007 Salamanca, Spain

Abstract

Carotid paragangliomas are infrequent tumours, generally single, non-functional and benign. Nevertheless, the biology of these tumours occasionally means they are bilateral, multicentric, functional and malignant. Such infrequency and the different ways they manifest themselves pose a diagnostic/therapeutic challenge that is reflected in the final outcomes.

According to the Shamblin classification, 75% of carotid paragangliomas are either Type I (tumour smaller than 4 cm, weakly attached to the carotid arteries, and can be surgically excised in a straightforward manner) or Type II (tumour larger than 4 cm, partially surrounding the carotid arteries, and attached to the vascular adventitia), and 25% of cases are Type III, completely surrounding the carotid bifurcation, firmly attached, so vessel replacement may be considered.

Fewer than 5% of carotid paragangliomas are associated with syndromes (e.g., von Hippel-Lindau disease and Carney triad) or diseases (e.g., thyroid cancer and thymoma), which further complicate their treatment. Morbidity and mortality rates in these cases are clearly different.

This review sets out to address carotid paragangliomas related to syndromes and diseases, with their references being very widely distributed in the literature, with the aim being to highlight their idiosyncrasies of clinical, diagnostic and therapeutic interest. This has involved a systematic literature review of the Medline and Cochrane Library databases up to 1 November 2019, locating 26 articles involving a total of 37 patients.

Conclusions: 1) Patients with these exceptional combinations present major clinical complexity; 2) They pose a medical challenge, with the diagnostic strategy being vitally important (search for associated synchronous and metachronous tumours) together with the therapeutic process (surgical times and priorities); and 3) There must be interdisciplinary cooperation across the different medical specialisms involved.

Keywords

Carotid body tumour, Carotid paraganglioma, Carotid paraganglioma complex, Hereditary tumour syndrome, Inherited syndromes

Abbreviations

PG: Paraganglioma; PHEO: Pheochromocytoma; CPG: Carotid Paraganglioma; JPG: Jugular Paraganglioma; HLD: vonHippel-Lindau Disease; MEN-2: Multiple Endocrine Neoplasia-type 2; NF-1: Neurofibromatosis-type 1; CSS: Carney-Stratakis Syndrome; GIST: Gastrointestinal Struma Tumour; PCH: Pulmonary Chondroma; HPT: Hyperplasia Parathyroid
Introduction

Although pheochromocytomas (PHEOs) and paragangliomas (PGs) share a common origin (neural crest-derived chromaffin cells), they are clearly different in terms of location (PHEOs - intra-adrenal paragangliomas (PGs) versus extra-adrenal ones) and biological behaviour. The term paraganglioma is used for tumours that arise from the sympathetic ganglia in the thorax, abdomen and pelvis, as well as the parasympathetic paraganglia in the head and neck. PGs account for 0.012% of all the tumours in the body, and for 0.6% of those located in the head and neck (80% affect the carotid body, 15% involve the glomus-jugular bulb and tympanic nerve, and the remaining 5% affect the vagus nerve) [1,2].

The rate of carotid paragangliomas (CPGs) is estimated to be between 1/30,000 and 1/100,000 people [3,4], affecting more women (ratio of 2:1) in their fifties (age range 18-94). The tumours are usually single ones measuring < 4 cm in diameter, delimited (not attached to the carotids), with slow growth, non-secretary, and benign [5-7].

According to the Shamblin classification [8], 75% of CPGs are either Type I (tumour smaller than 4 cm, weakly attached to the carotid arteries, and can be surgically excised in a straightforward manner) or Type II (tumour larger than 4 cm, partially surrounding the carotid arteries and attached to the vascular adventitia), and Type III with a frequency of 25% of cases, which completely surround the carotid bifurcation and are firmly attached, so vessel replacement may be considered.

Nevertheless, these tumours’ unpredictable biological behaviour and natural history lead to atypical forms (e.g., bilateral, multi-centric, functional, and malignant). Within these, there is a sub-group of CPGs related to different syndromes (von Hippel-Lindau disease, Carney triad, etc) and diseases (thyroid cancer, thymoma, etc), [9-12]. In most cases, these manifestations involve different systems, and present two major characteristics: a) A low rate, which means medical-surgical teams have little experience of them, and b) Diagnostic and therapeutic complexity; with both situations posing a challenge for doctors and surgeons.

This review seeks to adopt a unitary approach to these rare situations that are widely distributed throughout the literature on CPGs, with the aim being to understand and highlight their idiosyncrasies of clinical, diagnostic and therapeutic interest.

Systematic Literature Review

This review involved methodological aspects of the PRISMA statement [13] for a systematic approach.

Search methods: Two researchers (FSL and BGC) and a librarian (MMB) conducted a search in Medline (through PubMed) and the Cochrane Library (through Wiley) from their first records through to the end of the search (1 November 2019). No language restrictions have been applied, nor in terms of type of publication or date of the same. The search was conducted in English.


Exclusion criteria: a) Sporadic form to PGs, as these are the most frequent cases; b) Familiar form to PGs, relatively frequent cases, and related to PGL syndromes (PGL1 to PGL4). Our experience of the sporadic and familiar forms of CPG has recently been reported [14]; c) CPGs detected in infancy or during pregnancy, as there are recent reviews on the matter [15-19]; and d) CPGs associated with another extracranial ipsilateral carotid pathology (stenosis or aneurisms), as a recent review has been conducted by our group [20].

Data collection and analysis: A search has been made for CPGs related to form involving multiple systems - syndromes and diseases, which are to be found throughout the corresponding literature, with the aim being to highlight and understand their clinical, diagnostic and therapeutic interest.

The search found 457 potential publications, of which 229 were duplications. A reading of the titles and abstracts of the remaining 228 publications, examined separately by two researchers (FSL and BGC), led to 194 references being discarded. This meant that only 34 articles were considered relevant for our review. Following a reading of the full manuscripts, a further eight articles were discarded because they dealt with aspects that were collateral to the search’s core purpose. Finally, this review considered 26 publications (Figure 1). This low number, which is in turn spread across different syndromes and pathologies, does not permit the application of criteria of meta-analysis.

Results

The 26 articles selected [21-46] involve a total of 37 patients with a CPG associated with different syndromes and diseases (Table 1).

The articles included are basically reports on individual cases (12 in Europe, 10 in the US, and one in China), and short series (one in the US, and two in Mexico). Except for two written in German and Spanish, all the others are in English. The article in German was translated in full into English.

This review is divided into two main groups: a) CPGs related to syndromes (n = 17): Five to HLD, one to MEN-
Figure 1: Literature review flowchart.

2, one to NF-1, nine to the Carney triad, and one to the CSS; and b) CPGs related to other diseases/no syndromes (n = 20): Two to parathyroid adenomas, one to astrocytomas, nine to thyroid cancer, six to pituitary tumours, and two to thymomas.

Table 2 describes the characteristics by groups as follows:

- Gender: Nine males/15 females. This aspect was not reported in any of the other cases (13 patients).
- Patients’ average age at the time of the report: 41.9, with the younger ones in the syndromes group (29.5 vs. 46.1) (p = 0.012). No differences between genders.
- Characteristics of the CPGs: 10 bilateral cases (27%), a malignant one (2.7%) and one catecholamine secretor (2.7%).
- Synchronous or metachronous PG/PHEO (not including bilateral CPGs): 11 patients (29.7%); eight PHEOs (three of them bilateral) and 14 PGs with a different location in six patients (one patient with seven PGs and a bilateral PHEO). Greater frequency in syndromes (35.3% vs. 25%).
- Other tumours unrelated to the disease itself: Nine patients (45%), all in the group unrelated to syndromes; there were mostly adenomas, with different locations.
- Genetic study: 10 positive cases out of the 12 reported.
- Resection of the CPG: This was performed in 19 of the 22 cases reported (the three unoperated cases were as follows: One rejection of surgery, one surgery under way, and one patient deceased before surgery). The surgery performed on tumours associated with the CPG was usually sequential before or after the CPG (there are numerous cases of 3-4 sequential surgical procedures). There are only two reported cases of simultaneous surgery (CPG and thyroids).
Table 1: Carotid paragangliomas (CPG) related to syndromes and diseases. Literature review.

<table>
<thead>
<tr>
<th>Clinical situation</th>
<th>Authors, year [reference]</th>
<th>#</th>
<th>Age/sex</th>
<th>Side-CPG features</th>
<th>Other tumours (side)</th>
<th>Genetic test</th>
<th>Surgery (+)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPG &amp; Syndromes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>von Hippel-Lindau disease</td>
<td>Hull, et al. 1982 [32]</td>
<td>1</td>
<td>18/M</td>
<td>Right CPG malignant (metastasis)</td>
<td>PHEO (R)</td>
<td>NR</td>
<td>CPG, PHEO</td>
</tr>
<tr>
<td></td>
<td>Zanelli &amp; van der Walt, 1996 [45]</td>
<td></td>
<td>28/M</td>
<td>Left CPG</td>
<td>None</td>
<td>NR</td>
<td>CPG</td>
</tr>
<tr>
<td></td>
<td>Schimke, et al. 1998 [41]</td>
<td>1</td>
<td>NR</td>
<td>Right CPG functional</td>
<td>PHEOs, retinal angiomas, renal and pancreatic cysts</td>
<td>Positive</td>
<td></td>
</tr>
<tr>
<td>MEN-II</td>
<td>Erickson, et al. 2001 [29]</td>
<td>1</td>
<td>NR</td>
<td>Neck PG (possible CPG)</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Neurofibromatosis-type 1</td>
<td>Petr &amp; Else, 2018 [39]</td>
<td>1</td>
<td>NR</td>
<td>Neck PG (possible CPG)</td>
<td>Functional PG (thoracic sympathetic chain)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Camey, et al. 1999 [27]</td>
<td>7</td>
<td>NR</td>
<td>One case bilateral/Six unilateral CPG</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WIntermark, et al. 2001 [43]</td>
<td>1</td>
<td>18/F</td>
<td>Left CPG</td>
<td>GIST, PHEO (L)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nicholas, et al. 2015 [36]</td>
<td>1</td>
<td>39/M</td>
<td>Bilateral CPGs (R, large; L, small)</td>
<td>GIST, PHEO (R), PCH, PHEO, PGs abdominal</td>
<td>Positive</td>
<td></td>
</tr>
</tbody>
</table>

Note: NR = Not reported.
<table>
<thead>
<tr>
<th>CPG &amp; Diseases</th>
<th>Parathyroid adenoma</th>
<th>Astrocytoma</th>
<th>Thyroid carcinoma</th>
<th>Pituitary tumours</th>
<th>Thymoma</th>
<th>Thymoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophir, 1991 [37]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albores, et al. 1968 [22]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophir, 1991 [37]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huguet, et al. 2013 [31]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papathomas, et al. 2013 [38]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refior &amp; Mees, 2000 [40]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lin et al. 2019 [34]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papathomas, et al. 2013 [38]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refior &amp; Mees, 2000 [40]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lin et al. 2019 [34]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Ref.: Male F; Female, R; Right L; Left NR: Not Reported; PG: Paraganglioma (PGs, multiple); CPG: Carotid Paraganglioma; CPG + thyroid, Carotid Paraganglioma + Thyroid; PHEOs: Pheochromocytoma (bilateral); GIST: Gastrointestinal Stromal Tumour (GISTs, multiple); MEN: Multiple Endocrine Neoplasia; PCG (L): Pulmonary Chondroma; HPT: Hyperplasia parathyroid; (+) Simultaneous Surgery, ‘‘Cowden syndrome,’’ Dandy-Walker malformation.

Her father died of a cerebral astrocytoma and her mother underwent surgical removal of a large mediasinal PG; - ‘‘Cowden syndrome,’’ Dandy-Walker malformation.

<table>
<thead>
<tr>
<th>Right CPG</th>
<th>Left CPG</th>
<th>Bilateral CPGs</th>
<th>Right CPG</th>
<th>Left CPG</th>
<th>Bilateral CPGs</th>
<th>Left CPG</th>
<th>Right CPG</th>
<th>Left CPG</th>
<th>Right CPG</th>
<th>Left CPG</th>
<th>Right CPG</th>
<th>Left CPG</th>
<th>Right CPG</th>
<th>Left CPG</th>
<th>Right CPG</th>
<th>Left CPG</th>
</tr>
</thead>
<tbody>
<tr>
<td>56/F</td>
<td>55/F</td>
<td>52/F</td>
<td>43/M</td>
<td>43/F</td>
<td>58/F</td>
<td>51/M</td>
<td>51/M</td>
<td>51/M</td>
<td>51/M</td>
<td>51/M</td>
<td>51/M</td>
<td>51/M</td>
<td>51/M</td>
<td>51/M</td>
<td>51/M</td>
<td></td>
</tr>
<tr>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td>12/F</td>
<td></td>
</tr>
</tbody>
</table>

- M: Male; F: Female; R: Right; L: Left; NR: Not Reported; PG: Paraganglioma (PGs, multiple); CPG: Carotid Paraganglioma; CPG + thyroid, Carotid Paraganglioma + Thyroid; PHEOs: Pheochromocytoma (bilateral); MEN: Multiple Endocrine Neoplasia; PCG (L): Pulmonary Chondroma; HPT: Hyperplasia parathyroid; (+) Simultaneous Surgery.

Her father died of a cerebral astrocytoma and her mother underwent surgical removal of a large mediasinal PG; - ‘‘Cowden syndrome,’’ Dandy-Walker malformation.

<table>
<thead>
<tr>
<th>CPG &amp; Diseases</th>
<th>Parathyroid adenoma</th>
<th>Astrocytoma</th>
<th>Thyroid carcinoma</th>
<th>Pituitary tumours</th>
<th>Thymoma</th>
<th>Thymoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophir, 1991 [37]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albores, et al. 1968 [22]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ophir, 1991 [37]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huguet, et al. 2013 [31]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papathomas, et al. 2013 [38]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refior &amp; Mees, 2000 [40]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lin et al. 2019 [34]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papathomas, et al. 2013 [38]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refior &amp; Mees, 2000 [40]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lin et al. 2019 [34]</td>
<td>Parathyroid adenoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Ref.: Male F; Female, R; Right L; Left NR: Not Reported; PG: Paraganglioma (PGs, multiple); CPG: Carotid Paraganglioma; CPG + thyroid, Carotid Paraganglioma + Thyroid; PHEOs: Pheochromocytoma (bilateral); MEN: Multiple Endocrine Neoplasia; PCG (L): Pulmonary Chondroma; HPT: Hyperplasia parathyroid; (+) Simultaneous Surgery.

Her father died of a cerebral astrocytoma and her mother underwent surgical removal of a large mediasinal PG; - ‘‘Cowden syndrome,’’ Dandy-Walker malformation.
requiring vascular repair) (i.e., Shamblin’s Type III), se-
cretory (functional), multiple (including bilateral CPGs),
malign, residual/recurrent, treated by radiotherapy,
with adverse effects with embolization, etc. Morbidi-

ty and mortality rates are clearly different in complex
CPGs compared to simple ones. This latter group in-
cludes CPGs associated with syndromes (e.g., HLD), and
other pathologies (e.g. thyroid cancer), which inform
this review.

While the different forms of manifestation of com-
plex CPGs account for 1/4 of all CPGs, those associated
with syndromes and diseases are so rare that they in-
volve only a handful of individual cases or, exception-
ally, short series; an estimate of their frequency could be
around 0.8% of overall CPGs (the 37 cases in this review
out of the 5,000 CPGs reported in the literature) or the
3% of complex CPGs (37 out of 1,250 complex CPGs).

The embryological origin of PGs is the neural crest,
involving tumours in the diffuse neuroendocrine system
(formerly APUD). For this reason, and although many
are exceptional cases, and somewhat fewer among fa-
miliar forms, CPGs have been described associated
with diverse clinical situations. The latest way of classifying

Mortality: Recorded in only two cases. All other cas-
es being monitored/not reported.

Table 3 shows the high number of patients with

tumours unrelated to these syndromes/diseases; in-
cluding bilateral CPGs and other PGs/PHEOs and other
tumours (e.g., adenomas, leiomyomas, etc). There is a
difference between the two groups (p < 0.001).

**Discussion**

PGs in general and CPGs in particular are infrequent
tumours; in fact, the number of CPGs reported in Med-
line/PubMed does not exceed 5,000 patients [5,47].
However, despite their low rate, the PGs that affect the
carotid body are the most common among those in the
head and neck.

The majority of CPGs are single tumours, Types I or II
of the Shamblin classification (and therefore resectable
without affecting the carotid axis), non-secretary and
benign; with expert treatment, this normal presenta-
tion leads to excellent results. According to Al-Mefty
and Teixeira [48], the remaining CPGs are complex, with
one or more of the following characteristics: Very large,
attached to the carotid arteries (non-resectable or re-

N patients | CPG & Syndromes - Genetic + / - / NR | CPG & Diseases - Genetic + / - / NR | Total
---|---|---|---
With multi-tumours | 4 (23.5%)*1/0/3 | 15 (75%)*9/0/6 | 19 (51.4%) 10/0/9
Without multi-tumours | 6 (35.3%). 2/0/4 | 5 (25%) 1/2/2 | 11 (29.7%) 3/2/6
Not reported | 7 (41.2%) 0/0/7 | 0 | 7 (18.9%) 0/0/7
Total cases | 17 | 20 | 37

* Included bilateral CPG, other PGs and other tumour unrelated to these syndromes.
** Included bilateral CPG, other PGs/PHEOs and other tumour unrelated to these diseases (e.g., adenomas).
NR: Not reported.

CPG & Syndromes vs. CPG & Diseases: p < 0.001 (chi-squared test).

- Mortality: Recorded in only two cases. All other cas-
es being monitored/not reported.

Table 3: Multi-tumour and carotid paragangliomas (CPG) related to syndromes and diseases. Literature review.
1. Sporadic forms (the most frequent ones; there is a possibility of concealed paraganglioma)
2. Familial forms (relatively frequent) related to PGL syndromes:
   - PGL1 (mechanism detected in SDHD gene). Frequency in multicentric PGs.
   - PGL2 (genetic mechanism in SDHAF2 gene)
   - PGL3 (mechanism detected in SDHC gene)
   - PGL4 (mechanism detected in SDHB gene). Frequency in malignant forms.
3. Forms involving multiple systems (exceptionally associated with head and neck PGs):
   3.1. Associated with syndromes:
      - Von Hippel-Lindau (VHL) disease (mechanism detected in VHL gene)
      - Multiple endocrine neoplasia type II (mechanism detected in RET gene)
      - Neurofibromatosis type I (mechanism detected in NF1 gene)
      - Carney’s triad (unknown genetic mechanism, it may be familial)
   3.2. Not associated with syndromes (unknown genetic mechanisms):
      - Parathyroid adenoma
      - Astrocytoma
      - Thyroid carcinoma
      - Pituitary tumour
   4. Unknown associations: Thymoma

Table 4: Etiological/Molecular Classification of PGs of the Head and Neck.

1.. Sporadic forms (the most frequent ones; there is a possibility of concealed paraganglioma)
2. Familial forms (relatively frequent) related to PGL syndromes:
   - PGL1 (mechanism detected in SDHD gene). Frequency in multicentric PGs.
   - PGL2 (genetic mechanism in SDHAF2 gene)
   - PGL3 (mechanism detected in SDHC gene)
   - PGL4 (mechanism detected in SDHB gene). Frequency in malignant forms.
3. Forms involving multiple systems (exceptionally associated with head and neck PGs):
   3.1. Associated with syndromes:
      - Von Hippel-Lindau (VHL) disease (mechanism detected in VHL gene)
      - Multiple endocrine neoplasia type II (mechanism detected in RET gene)
      - Neurofibromatosis type I (mechanism detected in NF1 gene)
      - Carney’s triad (unknown genetic mechanism, it may be familial)
   3.2. Not associated with syndromes (unknown genetic mechanisms):
      - Parathyroid adenoma
      - Astrocytoma
      - Thyroid carcinoma
      - Pituitary tumour
   4. Unknown associations: Thymoma

Table 5: Syndromes related to PHEOs/Paragangliomas. Summary.

### Table 4: Etiological/Molecular Classification of PGs of the Head and Neck.

<table>
<thead>
<tr>
<th>Lesion in HLD</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cysts</td>
<td>Kidney, adrenal medulla, liver, lung, epididymis, omentum</td>
</tr>
<tr>
<td>Adenomas</td>
<td>Adrenal cortex, liver, kidney, exocrine pancreas</td>
</tr>
<tr>
<td>Hemangioblastomas</td>
<td>Cerebellum, retina, kidney, pancreas</td>
</tr>
<tr>
<td>Neoplasms</td>
<td>PHEO, islet cell tumour, meningioma, renal adenocarcinoma</td>
</tr>
<tr>
<td>Miscellanea</td>
<td>Polycythemia, syringomyelia, etc.</td>
</tr>
</tbody>
</table>

### Multiple Endocrine Neoplasia-type II (MEN-2) [29,49]


Prevalence: 1/40,000.

Mechanism detected: RET gene mutation.

**MEN-2A**
- Medullary thyroid cancer (100%)
- PHEO (40-50%)
- Parathyroid hyperplasia (20-30%)

**MEN-2B** (marfanoid habitus)
- Medullary thyroid cancer (100%)
- PHEO (50%)
- Multiple mucosal neuromas (> 95%)

### Neurofibromatosis-type 1 (NF1) [39,50]

Synonymous: Von Recklinghausen disease.

Prevalence: 1/3,000-4,000.

Autosomal dominant hereditary character.

Mechanism detected: NF1 gene mutation.

Clinically, tumours (neurofibromas) form in nerve tissues at the following levels:

a) Deep layer of skin (subcutaneous tissue).

b) Nerves of the brain (cranial nerves) and spinal cord (nerves or spinal pairs).
Carney triad [27,28,49]
Description: Carney (1977).
Prevalence: Unknown.
No inherited cases.
Mechanism detected: Unknown. Genetic defect remains elusive.
Triad: Gastrointestinal stromal tumours (GISTs) + PGs + Pulmonary chondromas.
Others lesions: Oesophageal leiomyomas, adrenocortical adenomas, PHEO.
Metastasis occurred in 10% of the patients.

Carney-Stratakis Syndrome (CSS) [36,51]
Description: Carney and Stratakis.
Prevalence: < 1/1,000,000 (probably more frequent than Carney triad).
Inherited autosomal dominant.
Mechanism detected: Germinal mutations SDHB, C and D genes, but not KIT or PDFGRA).
Dyad: GISTs + PGs. Not pulmonary chondromas.

PGs: Paragangliomas; PHEOs: Pheochromocytomas.

head and neck PGs, which logically include CPGs, is conducted from an etiological/molecular perspective [9,12] with our interest focusing on those forms that involve multiple systems, and which are exceptionally associated with a PG (Table 4).

There are, in this sense, several syndromes (HLD, MEN-2B, NF1, Carney triad and CSS) related to PG/PHEO in general and PGC in particular, whose more salient aspects are shown in Table 5. Although these syndromes cannot be grouped, it may be said that they are all rare and the majority are hereditary, and a genetic mutation has been identified as their mechanism. It may also be affirmed that clinically speaking they are defined by the appearance of different tumours, which appear in different organs, at an early stage and throughout a patient’s lifetime (metachronous).

CPGs very rarely occur in these syndromes. HLD [30,32,35,41,45] and the Carney triad [27,28,43] are the least rare situations (five and nine cases, respectively). They reflect the complexity of these associations, which prompt the need to detect the different tumours, establish therapeutic priorities, and always make joint treatment decisions with other specialisms.

A second group of pathologies associated with CPGs contains parathyroid adenomas, astrocytomas, thyroid carcinomas and pituitary tumours. These situations also involve multiple systems, although they are not associated with syndromes such as the aforementioned ones. There is currently no evidence whatsoever regarding the possible existence of some form of genetic mechanism.

The most frequent situation is the association between a CPG and thyroid papillary cancer - the most common anatomopathological form of thyroid cancer. We have found nine, with highlights being the major personal pathological antecedents (multicentric CPGs, simultaneous PHEO, tumours in other locations, etc.) which logically further complicate these patients’ treatment [21,22,26,31,34,38,46]. Simultaneous surgery (thyroids and CPG) has been performed successfully on two occasions [22,24]; the resection of a CPG and a full thyroidectomy in the same successful surgical procedure has also been reported in situations involving a benign pathology of the thyroids [52]. Nevertheless, the decision to perform concomitant or sequential surgery on these patients should always be made on a case-by-case basis.

Finally, when the first mention was made in 2000 of the coexistence of a CPG and a thymoma, a situation that had not been described before, the authors wondered whether it was a random finding [40]; nevertheless, a possible common neuroectodermic origin may explain the coexistence of the CPG and multiple endocrine tumours. Despite the scant existing experience, both tumours can be successfully removed [24].

The low frequency and highly varied clinical manifestation of CPGs (biology and natural history) render these associations extremely unusual, and they clearly pose a diagnostic and therapeutic challenge for doctors. This is reflected in the experience of the Mayo Clinic (Rochester, Minnesota), which in one of the broadest PG series in the literature (236 patients, including 117 CPGs) records the following casuistry: Five PGs associated with HLD (2.1%), one PG associated with MEN-2B (0.4%), and four PGs forming part of the Carney triad (1.5%) [29].

In short, CPGs are infrequent tumours, of which approximately 25% are complex cases; they include situations that are even more exceptional (the syndromes and pathologies described in this article) with around 1% of the CPGs (3% of the complex CPGs).

The diagnostic and therapeutic strategy is crucial in these cases. The complexity of these associations, sometimes multiple and rare, means there is no diagnostic-therapeutic consensus in the literature, and decisions need to be taken on a case-by-case basis. Table 6 presents some general criteria accordingly: The mandatory need to find functional and supposedly malignant tumours,


